Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial
Andrew Lotery, Sobha Sivaprasad, Abby O’Connell, et al.·2020·The Lancet